Reaktionsgleichung
[CH:1]1[CH:2]=[CH:3][C:4]2N(O)N=[N:7][C:5]=2C=1.CCN([CH:17]([CH3:19])C)C(C)C.CN([C:23]([O:27]N1N=NC2C=CC=NC1=2)=[N+](C)C)C.F[P-](F)(F)(F)(F)F.[Br:44]C1C(C(O)=O)=NC=CC=1.N1C=CN2CCNCC=12.[CH3:63][N:64]([CH:66]=[O:67])[CH3:65]>C(Cl)Cl>[Br:44][C:5]1[CH:4]=[CH:3][CH:2]=[C:1]([C:66]([N:64]2[CH2:65][CH2:19][C@@H:17]([O:27][CH3:23])[CH2:63]2)=[O:67])[N:7]=1Komponenten
8
Edukt 6
HCID 6228Dimethylformamide
HCID 757711-Hydroxybenzotriazole
HCID 81531Diisopropylethylamine
HCID 20501293-Bromopyridine-2-carboxylic Acid
HCID 9886157Methanaminium, N-((dimethylamino)(3H-1,2,3-triazolo(4,5-b)pyridin-3-yloxy)methylene)-N-methyl-, hexafluorophosphate(1-) (1:1)
HCID 132470465,6,7,8-Tetrahydroimidazo(1,2-a)pyrazineProdukt 1
Reagenzien, Katalysatoren, Lösungsmittel 1
Versuchsvorschrift
A solution of HOBt (148 mg, 0.97 mmol), DIEA (130 μL, 0.74 mmol), HATU (367 mg, 0.97 mmol), bromopyridine-2-carboxylic acid (150 mg, 0.74 mmol) and 5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine (91 mg, 0.74 mmol) in DMF (2.5 mL) was stirred overnight at 65° C. Upon completion, Si-carbonate (2.8 g, 2.23 mmol) and DCM (3 mL) were added and the mixture was shaken overnight at room temperature. The resulting mixture was then filtered, washed with DCM, concentrated in vacuo and purified by reverse phase HPLC (acetonitrile/water+formic acid modifier) to afford the title compound.
Aufarbeitung
- filtrationThe resulting mixture was then filtered
- washwashed with DCM
- concentrationconcentrated in vacuo
- custompurified by reverse phase HPLC (acetonitrile/water+formic acid modifier)
Quellen und Nachweise
- ORD-Eintrag
- ord-ef6d136ec9034e4880c918885b1dd270
- Quelldatensatz
- uspto-grants-2013_02
- Patentnummer
- US08367706B2
Verknüpfte Notizen
Wird geladen…